Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy
Prodrugs are chemically modified drug molecules that are inactive before administration. After administration, they are converted in situ to parent drugs and induce the mechanism of action. The development of prodrugs has upgraded conventional drug treatments in terms of bioavailability, targeting,...
Saved in:
Main Authors: | , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/165552 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-165552 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-1655522023-06-21T07:52:26Z Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy Ding, Chendi Chen, Chunbo Zeng, Xiaowei Chen, Hongzhong Zhao, Yanli School of Chemistry, Chemical Engineering and Biotechnology Science::Chemistry Biomedical Nanotechnology Cancer Therapy Prodrugs are chemically modified drug molecules that are inactive before administration. After administration, they are converted in situ to parent drugs and induce the mechanism of action. The development of prodrugs has upgraded conventional drug treatments in terms of bioavailability, targeting, and reduced side effects. Especially in cancer therapy, the application of prodrugs has achieved substantial therapeutic effects. From serendipitous discovery in the early stage to functional design with pertinence nowadays, the importance of prodrugs in drug design is self-evident. At present, studying stimuli-responsive activation mechanisms, regulating the stimuli intensity in vivo, and designing nanoscale prodrug formulations are the major strategies to promote the development of prodrugs. In this review, we provide an outlook of recent cutting-edge studies on stimuli-responsive prodrug nanosystems from these three aspects. We also discuss prospects and challenges in the future development of such prodrugs. National Research Foundation (NRF) Submitted/Accepted version This work was supported by the start-up fund (BS2021001) from Maoming People’s Hospital, the Guangdong Medical Science and Technology Research Fund (A2021213), the Programs Supported by Tianjin Key Laboratory of Biomedical Materials, the National Natural Science Foundation of China (32101065), and the Singapore National Research Foundation Investigatorship (NRF-NRFI2018-03). 2023-03-31T01:51:47Z 2023-03-31T01:51:47Z 2022 Journal Article Ding, C., Chen, C., Zeng, X., Chen, H. & Zhao, Y. (2022). Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy. ACS Nano, 16(9), 13513-13553. https://dx.doi.org/10.1021/acsnano.2c05379 1936-0851 https://hdl.handle.net/10356/165552 10.1021/acsnano.2c05379 9 16 13513 13553 en NRF-NRFI2018-03 ACS Nano This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Nano, copyright © 2022 American Chemical Society, after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acsnano.2c05379. application/pdf |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Science::Chemistry Biomedical Nanotechnology Cancer Therapy |
spellingShingle |
Science::Chemistry Biomedical Nanotechnology Cancer Therapy Ding, Chendi Chen, Chunbo Zeng, Xiaowei Chen, Hongzhong Zhao, Yanli Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy |
description |
Prodrugs are chemically modified drug molecules that are inactive before administration. After administration, they are converted in situ to parent drugs and induce the mechanism of action. The development of prodrugs has upgraded conventional drug treatments in terms of bioavailability, targeting, and reduced side effects. Especially in cancer therapy, the application of prodrugs has achieved substantial therapeutic effects. From serendipitous discovery in the early stage to functional design with pertinence nowadays, the importance of prodrugs in drug design is self-evident. At present, studying stimuli-responsive activation mechanisms, regulating the stimuli intensity in vivo, and designing nanoscale prodrug formulations are the major strategies to promote the development of prodrugs. In this review, we provide an outlook of recent cutting-edge studies on stimuli-responsive prodrug nanosystems from these three aspects. We also discuss prospects and challenges in the future development of such prodrugs. |
author2 |
School of Chemistry, Chemical Engineering and Biotechnology |
author_facet |
School of Chemistry, Chemical Engineering and Biotechnology Ding, Chendi Chen, Chunbo Zeng, Xiaowei Chen, Hongzhong Zhao, Yanli |
format |
Article |
author |
Ding, Chendi Chen, Chunbo Zeng, Xiaowei Chen, Hongzhong Zhao, Yanli |
author_sort |
Ding, Chendi |
title |
Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy |
title_short |
Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy |
title_full |
Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy |
title_fullStr |
Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy |
title_full_unstemmed |
Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy |
title_sort |
emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy |
publishDate |
2023 |
url |
https://hdl.handle.net/10356/165552 |
_version_ |
1772826297462947840 |